BRPI0717596B8 - compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreende - Google Patents
compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreendeInfo
- Publication number
- BRPI0717596B8 BRPI0717596B8 BRPI0717596A BRPI0717596A BRPI0717596B8 BR PI0717596 B8 BRPI0717596 B8 BR PI0717596B8 BR PI0717596 A BRPI0717596 A BR PI0717596A BR PI0717596 A BRPI0717596 A BR PI0717596A BR PI0717596 B8 BRPI0717596 B8 BR PI0717596B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- urea
- pharmaceutical composition
- ether compounds
- biaryl ether
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
compostos de eter biarílico uréia. a presente invenção relaciona-se a compostos de fórmula (i) (i) ou um sal farmaceuticamente aceitável dos mesmos; processos para a preparação dos compostos; intermediários utilizados na preparação dos compostos; composições contendo os compostos; e usos de compostos no tratemento de doenças ou condições associadas com atividade de amida hidrolase de ácido graxo (faah).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82996606P | 2006-10-18 | 2006-10-18 | |
US96521007P | 2007-08-17 | 2007-08-17 | |
PCT/IB2007/003202 WO2008047229A2 (en) | 2006-10-18 | 2007-10-05 | Biaryl ether urea compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0717596A2 BRPI0717596A2 (pt) | 2013-10-29 |
BRPI0717596B1 BRPI0717596B1 (pt) | 2020-04-14 |
BRPI0717596B8 true BRPI0717596B8 (pt) | 2021-05-25 |
Family
ID=39314409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0717596A BRPI0717596B8 (pt) | 2006-10-18 | 2007-10-05 | compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreende |
Country Status (39)
Country | Link |
---|---|
US (1) | US8044052B2 (pt) |
EP (1) | EP2076508B1 (pt) |
JP (1) | JP4434313B2 (pt) |
KR (1) | KR101181194B1 (pt) |
CN (1) | CN101595102B (pt) |
AP (1) | AP2780A (pt) |
AR (1) | AR063331A1 (pt) |
AT (1) | ATE493984T1 (pt) |
AU (1) | AU2007311591B2 (pt) |
BR (1) | BRPI0717596B8 (pt) |
CA (1) | CA2663984C (pt) |
CL (1) | CL2007003000A1 (pt) |
CR (2) | CR10701A (pt) |
CY (1) | CY1111170T1 (pt) |
DE (1) | DE602007011793D1 (pt) |
DK (1) | DK2076508T3 (pt) |
EA (1) | EA015488B1 (pt) |
ES (1) | ES2357340T3 (pt) |
GE (1) | GEP20125425B (pt) |
HK (1) | HK1139652A1 (pt) |
HN (1) | HN2007000407A (pt) |
HR (1) | HRP20110158T1 (pt) |
IL (1) | IL197664A (pt) |
MA (1) | MA30801B1 (pt) |
ME (1) | ME01308B (pt) |
MX (1) | MX2009004233A (pt) |
MY (1) | MY145460A (pt) |
NO (1) | NO342266B1 (pt) |
NZ (1) | NZ575624A (pt) |
PE (1) | PE20081265A1 (pt) |
PL (1) | PL2076508T3 (pt) |
PT (1) | PT2076508E (pt) |
RS (2) | RS20090154A (pt) |
SI (1) | SI2076508T1 (pt) |
TN (1) | TN2009000138A1 (pt) |
TW (1) | TWI404715B (pt) |
UY (1) | UY30649A1 (pt) |
WO (1) | WO2008047229A2 (pt) |
ZA (1) | ZA200902548B (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2937341B1 (en) | 2004-12-30 | 2017-07-05 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
CA2663984C (en) | 2006-10-18 | 2012-02-21 | Pfizer Products Inc. | Biaryl ether urea compounds |
TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
JP2011518145A (ja) * | 2008-04-17 | 2011-06-23 | ファイザー・インク | Faah阻害剤として有用な4−[3−(アリールオキシ)ベンジリデン]−3−メチルピペリジン5員アリールカルボキサミド化合物 |
WO2009127943A1 (en) * | 2008-04-17 | 2009-10-22 | Pfizer Inc. | Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
WO2009127946A1 (en) * | 2008-04-17 | 2009-10-22 | Pfizer Inc. | 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
US20110053949A1 (en) * | 2008-04-17 | 2011-03-03 | Pfizer Inc. | 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors |
EP2276735A1 (en) * | 2008-04-17 | 2011-01-26 | Pfizer Inc. | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors |
WO2010068452A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2010064597A1 (ja) * | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | ピペリジン誘導体 |
MX2011007424A (es) | 2009-01-12 | 2011-08-12 | Icagen Inc | Derivados de sulfonamida. |
WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
ES2493916T3 (es) | 2009-04-07 | 2014-09-12 | Infinity Pharmaceuticals, Inc. | Inhibidores de hidrolasa de amida de ácidos grasos |
WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
US8765735B2 (en) | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8927551B2 (en) | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8901111B2 (en) | 2009-06-05 | 2014-12-02 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
WO2011030798A1 (ja) | 2009-09-09 | 2011-03-17 | 大日本住友製薬株式会社 | 8-オキソジヒドロプリン誘導体 |
WO2011077313A1 (en) | 2009-12-22 | 2011-06-30 | Pfizer Inc. | Piperidinecarboxamides as mpges - 1 inhibitors |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
RU2569061C2 (ru) | 2010-02-03 | 2015-11-20 | Инфинити Фармасьютикалз, Инк. | Ингибиторы амид-гидролазы жирных кислот |
JP2013520489A (ja) | 2010-02-25 | 2013-06-06 | ファイザー・リミテッド | ペプチド類似体 |
US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
CA2804877A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
JP2013532186A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
CA2800971A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
KR20130133905A (ko) | 2011-04-05 | 2013-12-09 | 화이자 리미티드 | 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체 |
JP5898767B2 (ja) | 2011-07-13 | 2016-04-06 | ファイザー・リミテッドPfizer Limited | エンケファリン類似体 |
EP2758375A1 (en) * | 2011-09-23 | 2014-07-30 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
MX337469B (es) | 2011-10-26 | 2016-03-02 | Pfizer Ltd | Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. |
US9273011B2 (en) | 2011-10-28 | 2016-03-01 | Inhibitaxin Limited | Substituted pyridazines for the treatment of pain |
EP2791108B1 (en) | 2011-12-15 | 2016-07-27 | Pfizer Limited | Sulfonamide derivatives |
WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
WO2013102826A1 (en) | 2012-01-04 | 2013-07-11 | Pfizer Limited | N-aminosulfonyl benzamides |
EP2809655B1 (en) | 2012-02-03 | 2015-08-12 | Pfizer Inc | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
WO2014053968A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
CA2885247A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Tropomyosin-related kinase inhibitors |
WO2014053967A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
WO2018132533A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
CA3063102A1 (en) * | 2017-06-30 | 2019-01-03 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
CA3071861A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
JP7405834B2 (ja) * | 2018-08-24 | 2023-12-26 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ピリジニルメチレンピペリジン誘導体及びその使用 |
EA202192047A1 (ru) * | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
AU2022323513A1 (en) * | 2021-08-04 | 2024-02-22 | Jazz Pharmaceuticals Ireland Ltd. | Method of treating posttraumatic stress disorder |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB138405A (en) | 1919-01-16 | 1920-02-12 | Thomas Thompson | Improvements in or relating to suction or delivery valves for pumps |
GB1138405A (en) | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
GB1260886A (en) | 1969-06-20 | 1972-01-19 | Ici Ltd | Process for aryloxymethylmorpholine derivatives |
BE758766A (fr) | 1969-11-17 | 1971-05-10 | Ici Ltd | Nouveaux derives de la morpholine et de la |
BE759013R (fr) | 1969-11-17 | 1971-05-17 | Ici Ltd | Derives de la |
US4116665A (en) * | 1976-04-02 | 1978-09-26 | Eli Lilly And Company | Method of regulating the growth of aquatic weeds with pyridine derivatives |
IL56369A (en) | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
GB8424979D0 (en) * | 1984-10-03 | 1984-11-07 | Wyeth John & Brother Ltd | Benzenesulphonamide derivatives |
GB2167407B (en) | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
DK0619818T3 (da) | 1991-12-18 | 1996-11-25 | Schering Corp | Imidazoylalkyl substitueret med en seks-leddet nitrogenholdig heterocyclisk ring |
DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
AU7823894A (en) | 1993-08-27 | 1995-03-21 | Vrije Universiteit | New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor |
JP2978967B2 (ja) | 1995-01-11 | 1999-11-15 | 三進製藥株式會社 | 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物 |
US6271015B1 (en) * | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US6184242B1 (en) * | 1997-09-04 | 2001-02-06 | Syntex Usa (Llc) | 2-(substituted-phenyl)amino-imidazoline derivatives |
EP1068194B1 (en) | 1998-04-01 | 2003-11-05 | Janssen Pharmaceutica N.V. | Pde iv inhibiting pyridine derivatives |
CN1249038C (zh) | 1998-12-29 | 2006-04-05 | 法玛西雅厄普约翰美国公司 | 芳基醚的制备方法 |
PE20001566A1 (es) | 1999-03-26 | 2001-02-05 | Ucb Sa | Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas |
BR0009437A (pt) | 1999-03-31 | 2002-01-15 | Janssen Pharmaceutica Nv | Amido pré-gelatinizado em uma formulação de liberação controlada |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
WO2001025228A1 (fr) | 1999-10-07 | 2001-04-12 | Tadeka Chemical Industries, Ltd. | Derives d'amines |
US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
EP1263732A1 (en) | 2000-01-18 | 2002-12-11 | Pfizer Products Inc. | Corticotropin releasing factor antagonists |
KR20020073586A (ko) | 2000-02-11 | 2002-09-27 | 버텍스 파마슈티칼스 인코포레이티드 | 피페라진 및 피페리딘 유도체 |
GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
EP1263758A2 (en) | 2000-03-03 | 2002-12-11 | Ortho-McNeil Pharmaceutical, Inc. | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
JP2001303987A (ja) * | 2000-04-21 | 2001-10-31 | Toyota Motor Corp | 筒内噴射式内燃機関のスロットル制御装置 |
WO2001095856A2 (en) | 2000-06-15 | 2001-12-20 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
EP1385520A4 (en) | 2001-02-08 | 2007-03-21 | Nps Pharma Inc | METHODS AND COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRICAL DISEASES AND FOR THE IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT THEREOF |
EP1406889A2 (en) * | 2001-07-09 | 2004-04-14 | Pharmacia Italia S.p.A. | Interaction inhibitors of tcf-4 with beta-catenin |
AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
JP3865626B2 (ja) * | 2001-11-08 | 2007-01-10 | 株式会社ベステックスキョーエイ | パイプ部材 |
FR2833261B1 (fr) * | 2001-12-06 | 2004-07-02 | Yang Ji Chemical Company Ltd | Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii |
US20040063726A1 (en) * | 2002-02-08 | 2004-04-01 | Artman Linda D | Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same |
WO2003075929A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
AU2003220184A1 (en) | 2002-03-20 | 2003-10-08 | Schering Aktiengesellschaft | Substituted piperazine antithrombotic pai-1 inhibitors |
TWI283241B (en) | 2002-05-29 | 2007-07-01 | Tanabe Seiyaku Co | Novel piperidine compound |
EP1572311A4 (en) | 2002-10-21 | 2007-12-12 | Janssen Pharmaceutica Nv | ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDHYDROLASE |
TW200505902A (en) * | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
MXPA05010444A (es) | 2003-04-03 | 2005-11-04 | Merck Patent Gmbh | Compuestos de carbonilo. |
SE0301443D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
SE0301442D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations therof and uses thereof |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
GB0325287D0 (en) | 2003-10-29 | 2003-12-03 | Merck Sharp & Dohme | Therapeutic agents |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
EP1689739B1 (en) * | 2003-12-03 | 2016-03-30 | YM BioSciences Australia Pty Ltd | Azole-based kinase inhibitors |
WO2005075472A1 (en) * | 2004-02-03 | 2005-08-18 | Janssen Pharmaceutica, N.V. | 3-(diheteroarylnethylene)-8-azabicyclo[3.2.1]octane and 3-(aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives |
JP2007532551A (ja) * | 2004-04-09 | 2007-11-15 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害剤 |
US20080103209A1 (en) * | 2004-04-23 | 2008-05-01 | The Regents Of The University Of California | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists |
SE0401343D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
PE20060530A1 (es) | 2004-06-04 | 2006-06-28 | Arena Pharm Inc | Aril y heteroaril derivados sustituidos como moduladores del metabolismo de la glucosa |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2006034341A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
DE102004045796A1 (de) | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
WO2006035303A1 (en) | 2004-09-29 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US7491720B2 (en) * | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
GT200500375A (es) * | 2004-12-20 | 2006-11-28 | Derivados de piperidina y su uso como agentes antiinflamatorios | |
MX2007007553A (es) | 2004-12-24 | 2007-08-15 | Prosidion Ltd | Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes. |
WO2006067401A1 (en) | 2004-12-24 | 2006-06-29 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
EP2937341B1 (en) | 2004-12-30 | 2017-07-05 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
CA2597131A1 (en) | 2005-02-10 | 2006-08-17 | Warner-Lambert Company Llc | Fatty acid amide hydrolase assay |
US7750011B2 (en) * | 2005-02-15 | 2010-07-06 | Neurosearch A/S | Diazabicyclic aryl derivatives and their medical use |
KR101063585B1 (ko) | 2005-02-17 | 2011-09-07 | 아스텔라스세이야쿠 가부시키가이샤 | 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체 |
US20090082435A1 (en) | 2005-04-28 | 2009-03-26 | The Regents Of The University Of California | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
WO2006129842A1 (ja) | 2005-06-01 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
WO2006137465A1 (ja) | 2005-06-24 | 2006-12-28 | Shionogi & Co., Ltd. | 含窒素複素環誘導体 |
WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
PE20070099A1 (es) | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
BRPI0615248A2 (pt) | 2005-08-26 | 2009-07-14 | Shionogi & Co | derivado tendo atividade agonista de ppar |
US7131609B1 (en) | 2005-08-31 | 2006-11-07 | Kimberly-Clark Worldwide, Inc. | Dispenser for sheet material |
JP2009522287A (ja) | 2005-12-29 | 2009-06-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | 脂肪酸アミド加水分解酵素阻害剤 |
US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
WO2007103456A2 (en) | 2006-03-06 | 2007-09-13 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
WO2008021625A2 (en) | 2006-08-18 | 2008-02-21 | N.V. Organon | Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
US7888394B2 (en) | 2006-08-21 | 2011-02-15 | N.V. Organon | Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors |
EP2065369A4 (en) | 2006-08-23 | 2011-12-28 | Astellas Pharma Inc | UREA CONNECTION OR SALT THEREOF |
US20080089845A1 (en) | 2006-09-07 | 2008-04-17 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
US20090099240A1 (en) | 2006-10-02 | 2009-04-16 | N.V. Organon | Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
CA2663984C (en) | 2006-10-18 | 2012-02-21 | Pfizer Products Inc. | Biaryl ether urea compounds |
US20080119549A1 (en) | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
NZ552238A (en) | 2006-12-20 | 2009-07-31 | Seperex Nutritionals Ltd | An extract |
CN101686979A (zh) | 2007-05-25 | 2010-03-31 | 詹森药业有限公司 | 脂肪酸酰胺水解酶的杂芳基取代的脲调节剂 |
-
2007
- 2007-10-05 CA CA2663984A patent/CA2663984C/en active Active
- 2007-10-05 SI SI200730534T patent/SI2076508T1/sl unknown
- 2007-10-05 GE GEAP200711226A patent/GEP20125425B/en unknown
- 2007-10-05 JP JP2009532909A patent/JP4434313B2/ja active Active
- 2007-10-05 MX MX2009004233A patent/MX2009004233A/es active IP Right Grant
- 2007-10-05 DE DE602007011793T patent/DE602007011793D1/de active Active
- 2007-10-05 RS RSP-2009/0154A patent/RS20090154A/sr unknown
- 2007-10-05 KR KR1020097007835A patent/KR101181194B1/ko active IP Right Grant
- 2007-10-05 CN CN2007800389592A patent/CN101595102B/zh active Active
- 2007-10-05 WO PCT/IB2007/003202 patent/WO2008047229A2/en active Application Filing
- 2007-10-05 DK DK07848827.7T patent/DK2076508T3/da active
- 2007-10-05 PT PT07848827T patent/PT2076508E/pt unknown
- 2007-10-05 BR BRPI0717596A patent/BRPI0717596B8/pt active IP Right Grant
- 2007-10-05 PL PL07848827T patent/PL2076508T3/pl unknown
- 2007-10-05 EA EA200970296A patent/EA015488B1/ru not_active IP Right Cessation
- 2007-10-05 ES ES07848827T patent/ES2357340T3/es active Active
- 2007-10-05 AT AT07848827T patent/ATE493984T1/de active
- 2007-10-05 AU AU2007311591A patent/AU2007311591B2/en active Active
- 2007-10-05 ME MEP-2011-49A patent/ME01308B/me unknown
- 2007-10-05 EP EP07848827A patent/EP2076508B1/en active Active
- 2007-10-05 RS RS20110107A patent/RS51647B/en unknown
- 2007-10-05 NZ NZ575624A patent/NZ575624A/en unknown
- 2007-10-05 AP AP2009004821A patent/AP2780A/xx active
- 2007-10-17 PE PE2007001407A patent/PE20081265A1/es active IP Right Grant
- 2007-10-17 AR ARP070104596A patent/AR063331A1/es active IP Right Grant
- 2007-10-17 TW TW096138933A patent/TWI404715B/zh active
- 2007-10-17 UY UY30649A patent/UY30649A1/es not_active Application Discontinuation
- 2007-10-18 US US11/874,577 patent/US8044052B2/en active Active
- 2007-10-18 CL CL200703000A patent/CL2007003000A1/es unknown
- 2007-10-19 HN HN2007000407A patent/HN2007000407A/es unknown
-
2009
- 2009-03-18 IL IL197664A patent/IL197664A/en active IP Right Grant
- 2009-03-27 MY MYPI20091261A patent/MY145460A/en unknown
- 2009-03-31 CR CR10701A patent/CR10701A/es unknown
- 2009-04-14 ZA ZA200902548A patent/ZA200902548B/xx unknown
- 2009-04-14 TN TNP2009000138A patent/TN2009000138A1/fr unknown
- 2009-04-17 MA MA31798A patent/MA30801B1/fr unknown
- 2009-04-20 NO NO20091560A patent/NO342266B1/no unknown
-
2010
- 2010-05-31 HK HK10105310.0A patent/HK1139652A1/xx unknown
-
2011
- 2011-02-08 CY CY20111100140T patent/CY1111170T1/el unknown
- 2011-03-04 HR HR20110158T patent/HRP20110158T1/hr unknown
-
2014
- 2014-06-27 CR CR20140313A patent/CR20140313A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0717596B8 (pt) | compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreende | |
BR112015005972A2 (pt) | derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj | |
BR112012011793A2 (pt) | "acrilamidas heterocíclicas e seu uso como farmacêuticos" | |
CR20110016A (es) | Compuestos quimicos 251 | |
BRPI0513891B8 (pt) | derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes | |
BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
BRPI0710527B8 (pt) | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende | |
BRPI0805826B8 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
BR112014010576A8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
BR112014009102A2 (pt) | compostos químicos | |
BRPI0924183B8 (pt) | inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica | |
UY31639A1 (es) | Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones | |
BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
UY30481A1 (es) | Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos. | |
BR112013011634A2 (pt) | derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c] | |
BRPI0706992C8 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BRPI0712631B8 (pt) | compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações | |
BRPI0507622A (pt) | composto baseado em ácido hialurÈnico, sal de sódio, processo para preparar um composto ou um seu sal, composição farmacêutica, produto medicinal e dispositivo médico para uso humano ou veterinário, e, uso de composto ou de seu sal | |
BR112015001207A8 (pt) | derivados de carbamato/ureia, seus usos, composição farmacêutica, forma livre e seu método de preparação | |
BR112022000782A2 (pt) | Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica | |
BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |